PharmaShots | Incisive News in 3 Shots

Subscribe Now

Emgality

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III Studies to Treat Low- and High-Frequency Episodic Migraine

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III Studies to Treat Low- and High-Frequency Episodic Migraine

May 7, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us